StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSOFree Report) in a research report released on Friday. The brokerage issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reiterated a neutral rating and set a $1.00 target price on shares of Cytosorbents in a report on Tuesday, May 7th.

Get Our Latest Stock Report on Cytosorbents

Cytosorbents Stock Up 12.3 %

CTSO opened at $0.91 on Friday. Cytosorbents has a one year low of $0.78 and a one year high of $4.29. The company has a market cap of $49.40 million, a price-to-earnings ratio of -1.54 and a beta of 0.62. The business’s fifty day moving average is $0.90 and its two-hundred day moving average is $1.10. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77.

Cytosorbents (NASDAQ:CTSOGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 125.40%. The firm had revenue of $9.79 million for the quarter, compared to analysts’ expectations of $9.78 million. During the same period in the prior year, the company earned ($0.17) EPS. Analysts anticipate that Cytosorbents will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC raised its position in shares of Cytosorbents by 84.0% in the third quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock valued at $67,000 after buying an additional 16,598 shares during the last quarter. Key Client Fiduciary Advisors LLC raised its holdings in Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 22,557 shares during the last quarter. Raymond James & Associates purchased a new stake in shares of Cytosorbents in the fourth quarter valued at $56,000. Sargent Investment Group LLC increased its stake in Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after purchasing an additional 51,699 shares during the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after buying an additional 299,103 shares during the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

(Get Free Report)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Recommended Stories

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.